While ex vivo donor T cell depletion (TCD) is highly effective for lethal GVHD prevention, T cell removal may compromise beneficial donor T-cell responses. Rather than broadly eliminate T-cells or T-cell subsets, the applicant proposes to functionally alter in vitro the small proportion of murine donor CD4+ T cells with anti-host alloreactive potential. A common feature of his strategy will be in the in vitro blockade of the CD28/CTLA4 T-cell costimulatory pathway since there is evidence that T cells can be rendered specifically tolerant of alloantigen present during the blockade (termed anergy). In vitro assays will be used to screen for conditions that favor the anergy development. The applicant has established criteria for the acceptable level of reduction of donor anti- host and anti-third party alloreactivity which will be required before proceeding with the in vivo testing of the GVHD properties of anergic donor cells. His initial studies will be focused on CD4+ T cells since these appear to be most susceptible to anergy induction. Anergic CD4+ T cells will be infused in vivo without any supplemental in vivo GVHD preventive reagents. Because IL-2 responses can override anergy induction in some situations, the applicant has designed experiments to address whether IL-2 production will prevent anergy induction in vitro or GVHD prevention in vivo. If necessary, he will target, in the context of optimal CD28/CTLA4 blockade, a limited number of other pathways which can cause T cells to proliferate in the presence of CD28/CTLA4 blockade. By using appropriate specificity controls and examining responses to relevant peptides given in vivo post- transplantation, he will determine if in vitro anergy induction is translatable into beneficial in vivo effects. These principles and strategies will be applied with suitable modifications to a CD8+ T cell mediated GVHD system. To determine how these approaches have altered the in vivo GVHD potential of the donor cells, the applicant will need to examine specifically those donor T cells that are exclusively alloreactive with the host. Because equal to or less than 0.1% of donor T cells have anti- host alloreactivity, the applicant will use T cell receptor transgenic mice as donors since more than 90% of all T cells will have an obligate alloreactivity to the recipients. To determine if anergy is preserved in vivo, phenotypic and functional assays of early post-bone marrow transplantation (BMT) alloreactive donor T cells, isolated by thoracic duct cannulation (TDC), will be performed. A highly enriched source of donor T cells can be obtained by TDC which can be studied for alloantigen and anti-peptide responses.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
1R01HL056067-01
Application #
2234680
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Project Start
1995-08-01
Project End
1998-07-31
Budget Start
1995-08-01
Budget End
1996-07-31
Support Year
1
Fiscal Year
1995
Total Cost
Indirect Cost
Name
University of Minnesota Twin Cities
Department
Pediatrics
Type
Schools of Medicine
DUNS #
168559177
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Sarhan, Dhifaf; Hippen, Keli L; Lemire, Amanda et al. (2018) Adaptive NK Cells Resist Regulatory T-cell Suppression Driven by IL37. Cancer Immunol Res 6:766-775
Li, Yue; Guan, Xiaoqun; Liu, Weiren et al. (2018) Helminth-Induced Production of TGF-? and Suppression of Graft-versus-Host Disease Is Dependent on IL-4 Production by Host Cells. J Immunol 201:2910-2922
Li, Yue; Liu, Weiren; Guan, Xiaqun et al. (2018) STAT6 and Furin Are Successive Triggers for the Production of TGF-? by T Cells. J Immunol 201:2612-2623
Bachanova, Veronika; Sarhan, Dhifaf; DeFor, Todd E et al. (2018) Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells. Cancer Immunol Immunother 67:483-494
Blazar, Bruce R; MacDonald, Kelli P A; Hill, Geoffrey R (2018) Immune regulatory cell infusion for graft-versus-host disease prevention and therapy. Blood 131:2651-2660
Zitzer, Nina C; Snyder, Katiri; Meng, Xiamoei et al. (2018) MicroRNA-155 Modulates Acute Graft-versus-Host Disease by Impacting T Cell Expansion, Migration, and Effector Function. J Immunol 200:4170-4179
Hülsdünker, Jan; Ottmüller, Katja J; Neeff, Hannes P et al. (2018) Neutrophils provide cellular communication between ileum and mesenteric lymph nodes at graft-versus-host disease onset. Blood 131:1858-1869
Zhang, Ping; Lee, Jason S; Gartlan, Kate H et al. (2017) Eomesodermin promotes the development of type 1 regulatory T (TR1) cells. Sci Immunol 2:
Koehn, Brent H; Blazar, Bruce R (2017) Role of myeloid-derived suppressor cells in allogeneic hematopoietic cell transplantation. J Leukoc Biol 102:335-341
Varelias, Antiopi; Ormerod, Kate L; Bunting, Mark D et al. (2017) Acute graft-versus-host disease is regulated by an IL-17-sensitive microbiome. Blood 129:2172-2185

Showing the most recent 10 out of 167 publications